RET mutation and increased angiogenesis in medullary thyroid carcinomas

Endocrine-Related Cancer

Volumn 23, Issue 8, 2016, Pages 665-676

  Verrienti, Antonella ^a   Tallini, Giovanni ^b   Colato, Chiara ^c   Boichard, Amélie ^d   Checquolo, Saula ^a   Pecce, Valeria ^a   Sponziello, Marialuisa ^a   Rosignolo, Francesca ^a   De Biase, Dario ^b   Rhoden, Kerry ^b   Casadei, Gian Piero ^e   Russo, Diego ^f   Visani, Michela ^b   Acquaviva, Giorgia ^b   Ferdeghini, Marco ^c   Filetti, Sebastiano ^a   Durante, Cosimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^d CNRS UMS3655   (France)

^e Azienda USL di Bologna   (Italy)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Angiogenesis; Medullary thyroid cancer; Pericyte; RET mutations

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; MESSENGER RNA; NOTCH3 RECEPTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PODOPLANIN; PROTEIN RET; VASCULOTROPIN RECEPTOR 1; FLT4 PROTEIN, HUMAN; KDR PROTEIN, HUMAN; NOTCH3 PROTEIN, HUMAN; RET PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL PARAMETERS; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; MICROVASCULARIZATION; PERICYTE; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA; UPREGULATION; CARCINOMA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROVASCULATURE; MUTATION; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION; THYROID TUMOR; TUMOR CELL LINE;

CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROVESSELS; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR, NOTCH3; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84989306653     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-16-0132     Document Type: Article

References (39)

1. Azzi S, Hebda JK & Gavard J 2013 Vascular permeability and drug delivery in cancers. Frontiers in Oncology 3 211-211. (doi: 10. 3389/ fonc. 2013. 00211)
2. Bagheri-Yarmand R, Sinha KM, Gururaj AE, Ahmed Z, Rizvi YQ, Huang SC, Ladbury JE, Bogler O, Williams MD, Cote GJ, et al. 2015 A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis. Journal of Biological Chemistry 290 11749-11761. (doi: 10. 1074/ jbc. M114. 619833)
3. Baluk P, Morikawa S, Haskell A, Mancuso M & McDonald DM 2003 Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. American Journal of Pathology 163 1801-1815. (doi: 10. 1016/S0002-9440(10)63540-7)
4. Bergers G & Song S 2005 The role of pericytes in blood-vessel formation and maintenance 1. Neuro-Oncology 7 452-464. (doi: 10. 1215/ S1152851705000232)
5. Bergers G, Song S, Meyer-morse N, Bergsland E & Hanahan D 2003 Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation 111 1287-1295. (doi: 10. 1172/JCI200317929)
6. Boichard A, Croux L, Ghuzlan AA, Broutin S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM & Lacroix L 2015 Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 97 2031-2035. (doi: 10. 1210/jc. 2012-2092)
7. Carmeliet P, Smet FD, Loges S & Mazzone M 2009 Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nature Reviews. Clinical Oncology 6 315-326. (doi: 10. 1038/ nrclinonc. 2009. 64)
8. Castellone MD, Verrienti A, Magendra Rao D, Sponziello M, Fabbro D, Muthu M, Durante C, Maranghi M, Damante G, Pizzolitto S, et al. 2010 A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization. Clinical Endocrinology 73 529-534. (doi: 10. 1111/j. 1365-2265. 2009. 03757. x)
9. Chau NG & Haddad RI 2013 Vandetanib for the treatment of medullary thyroid cancer. Clinical Cancer Research 19 524-530. (doi: 10. 1158/1078-0432. CCR-12-2353)
10. Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM, et al. 2013 Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 23 1-4. (doi: 10. 1089/thy. 2013. 2301. ob)
11. de Groot JWBD, Menacho IP, Schepers H, Osinga J, Eggen BJL & Hofstra RMW 2006 Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 139 806-814. (doi: 10. 1016/ j. surg. 2005. 10. 019)
12. Deshpande H, Roman S, Thumar J & Sosa JA 2011 Vandetanib (ZD6474) in the treatment of medullary thyroid cancer. Clinical Medicine Insights Oncology 5 213-221. (doi: 10. 4137/cmo. s6197)
13. Durante C & Filetti S 2011 Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography. Journal of Clinical Endocrinology and Metabolism 96 3059-3061. (doi: 10. 1210/jc. 2011-1379)
14. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH & Augustin HG 2000 Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Research 60 1388-1393.
15. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes H-P, Menger MD, Ullrich A & Vajkoczy P 2003 Combined inhibition of VEGF-and PDGF-signaling en-forces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB Journal 18 338-340. (doi: 10. 1096/fj. 03-0271fje)
16. Ferreira CV & Maia AL 2013 Advanced medullary thyroid cancer: pathophysiology and management. Cancer Management and Research 5 57-66. (doi: 10. 2147/cmar. s33105)
17. Garcia A & Kandel JJ 2012 Notch: A key regulator of tumor angiogenesis and metastasis. Histology and Histopathology 27 151-156. (doi: 10. 14670/HH-27. 151)
18. Kim BH, Sohn JC, Ha JY, Park CH, Choe MS, Jung HR & Kim CI 2014 Relationships between the effect of sunitinib and immature blood vessels in metastatic renal cell cancer. Urologia Internationalis 94 137-143. (doi: 10. 1159/000363773)
19. Longo DL 2012 Tumor heterogeneity and personalized medicine. New England Journal of Medicine 366 883-892. (doi: 10. 1056/ NEJMe1200656)
20. Mancikova V, Kersten I, Leandro-garc? LJ, Sa L, Sastre-marcos J, Garc? JF & Rodr? C 2014 Expression is influenced by RAS mutations in medullary thyroid carcinoma. Thyroid 24 1251-1255. (doi: 10. 1089/ thy. 2013. 0579)
21. Mitchell JC & Parangi S 2005 Angiogenesis in benign and malignant thyroid disease. Thyroid 15 494-510. (doi: 10. 1089/thy. 2005. 15. 494)
22. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK & McDonald DM 2002 Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. American Journal of Pathology 160 985-1000. (doi: 10. 1016/S0002-9440(10)64920-6)
23. Phng L & Gerhardt H 2009 Review angiogenesis: A team effort coordinated by notch. Developmental Cell 16 196-208. (doi: 10. 1016/ j. devcel. 2009. 01. 015)
24. Puppin C, Durante C, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A, Lacroix L, et al. 2014 Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. Endocrine 47 528-536. (doi: 10. 1007/s12020-014-0204-3)
25. Pusztaszeri MP, Bongiovanni M & Faquin WC 2014 Update on the cytologic and molecular features of medullary thyroid carcinoma. Advances in Anatomic Pathology 21 26-35. (doi: 10. 1097/ PAP. 0000000000000004)
26. Raza A, Franklin MJ & Dudek AZ 2010 Critical review pericytes and vessel maturation during tumor angiogenesis and metastasis. American Journal of Hematology 85 593-598. (doi: 10. 1002/ajh. 21745)
27. Ribatti D, Nico B & Crivellato E 2011 The role of pericytes in angiogenesis. International Journal of Developmental Biology 55 261-268. (doi: 10. 1387/ijdb. 103167dr)
28. Ribeiro AL & Okamoto OK 2015 Combined effects of pericytes in the tumor microenvironment. Stem Cells International 2015 1-8. (doi: 10. 1155/2015/868475)
29. Roca C & Adams RH 2007 Regulation of vascular morphogenesis by Notch signaling. Genes and Development 21 2511-2524. (doi: 10. 1101/ gad. 1589207)
30. Rodriguez-Antona C, Munoz-Repeto I, Inglada-Perez L, de Cubas AA, Mancikova V, Canamero M, Maliszewska A, Gomez A, Leton R, Leandro-Garcia LJ, et al. 2013 Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma. Endocrine-Related Cancer 20 611-619. (doi: 10. 1530/ERC-12-0316)
31. Sakurai T & Kudo M 2011 Signaling pathways governing tumor angiogenesis. Oncology 81 24-29. (doi: 10. 1159/000333256)
32. Sherman SI, Cohen EEW, Schoffski P, Elisei R, Schlumberger M, Wirth LJ, Mangeshkar M, Aftab DT, Clary DO & Brose MS 2013 Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: results from a phase III study. Journal of Clinical Oncology 31 (May 20 Supplement) abstract 6000. (available at: http: //meeting. ascopubs. org/cgi/ content/abstract/31/15-suppl/6000)
33. Sponziello M, Durante C, Boichard A, Dima M, Puppin C, Verrienti A, Tamburrano G, Di Rocco G, Redler A, Lacroix L, et al. 2014 Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. Molecular and Cellular Endocrinology 392 8-13. (doi: 10. 1016/j. mce. 2014. 04. 016)
34. Stapor PC, Sweat RS, Dashti DC, Betancourt AM & Murfee WL 2014 Pericyte dynamics during angiogenesis: new insights from new identities. Journal of Vascular Research 51 163-174. (doi: 10. 1159/000362276)
35. Tallini G, Ghossein RA, Emanuel J, Gill J, Kinder B, Dimich AB, Costa J, Robbins R, Burrow GN & Rosai J 1998 Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. Journal of Clinical Oncology 16 1158-66.
36. Thomas J-L, Aphp F, Pitié-salpètrière GH, Baker K, Pierre U, Paris MC, Nurmi H & France CD 2013 Interactions between VEGFR and Notch signaling pathways in endothelial and neural cells. Cellular and Molecular Life Sciences 70 1779-1792. (doi: 10. 1007/ s00018-013-1312-6)
37. Turner HE, Harris AL, Melmed S & Wass JAH 2003 Angiogenesis in endocrine tumors. Endocrine Reviews 24 600-632. (doi: 10. 1210/ er. 2002-0008)
38. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, et al. 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25 567-610. (doi: 10. 1089/ thy. 2014. 0335)
39. Wu LS, Roman SA & Sosa JA 2011 Medullary thyroid cancer: An update of new guidelines and recent developments. Current Opinion in Oncology 23 22-27. (doi: 10. 1097/CCO. 0b013e328340b527)